Figure S2 from De novo and histologically transformed small cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways. | Synapse
September 16, 2024
Figure S2 from De novo and histologically transformed small cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways.
Key Points
Key points are not available for this paper at this time.
Abstract
Figure S2. Lurbinectedin sensitivity (IC50) correlation with MYC expression and changes in expression of NE markers.